BridgeMD
Compares treatment options for Post-ERCP Pancreatitis
Official title Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis
ClinicalTrials.gov ID: NCT07088757
What this study is testing
What is standard dose indomethacin?
standard dose indomethacin is an investigational medicine, being studied as a potential treatment for post-ercp pancreatitis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Endoscopic Retrograde Cholangiopancreatography (ERCP) is a widely used procedure for diagnosing and treating pancreatic and biliary diseases. Despite its benefits, ERCP carries a risk of post-procedure pancreatitis (PEP), which occurs in approximately 12.2% of cases and can significantly increase healthcare costs and patient morbidity.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults aged 18 years or older.
- Patients planned to undergo Endoscopic Retrograde Cholangiopancreatography
You likely can't join if
- Standard contraindications to ERCP
- Allergy to Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Use of NSAIDs within 7 days prior to ERCP
- Not suitable for NSAIDs administration (gastrointestinal hemorrhage within 4 weeks, renal dysfunction [Cr \>1.4mg/dl=120umol/l]; presence of...
- Acute pancreatitis within 3 days before ERCP
- Hemodynamic instability
See the full eligibility criteria
- Adults aged 18 years or older.
- Patients planned to undergo Endoscopic Retrograde Cholangiopancreatography
- Standard contraindications to ERCP
- Allergy to Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Use of NSAIDs within 7 days prior to ERCP
- Not suitable for NSAIDs administration (gastrointestinal hemorrhage within 4 weeks, renal dysfunction [Cr \>1.4mg/dl=120umol/l]; presence of coagulopathy before the procedure)
- Acute pancreatitis within 3 days before ERCP
- Hemodynamic instability
- Pregnancy or lactation
- Patients who are unwilling or unable to provide informed consent
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
- Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China; Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.